E-cadherin regulates female tumor aggressiveness by controlling estrogen-sensitivity [ChIP-seq]
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA995537 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR25304681_1.fastq.gz | Fastqsanger.gz | |||
| SRR25304681_2.fastq.gz | Fastqsanger.gz | |||
| SRR25304682_1.fastq.gz | Fastqsanger.gz | |||
| SRR25304682_2.fastq.gz | Fastqsanger.gz | |||
| SRR25304683_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 26 |
Similar Datasets
Project description:Sex disparities in cancer have been documented, but understanding of the underlying mechanisms is still limited, restricting precision medicine and the discovery of new therapeutic options. By analyzing overall cancer frequency, we found that women, between puberty and menopause, are more prone to develop cancer than men. We identified the cell adhesion molecule, E-cadherin, as a central node of the estrogen response in multiple cancers. Using original mouse melanoma model, a cancer with a higher incidence of women than in men during this period, we identify a previously unknown estrogen-sensitizing signaling pathway linking E-cadherin to the Estrogen Receptor and to the Gastrin Releasing Peptide Receptor (GRPR), promoting melanoma aggressiveness in female only. Inhibition of this axis through GRPR targeting suppress metastasis in mice, representing a very promising therapeutic approach. Our results demonstrate that E-cadherin prevents carcinoma sensitivity to estrogens and identify a new therapeutic avenue to treat women suffering from multiple E-cadherin-dependent cancers.
2025-04-21 | GSE237500 | GEO
Project description:The Keratin 17/YAP/IL6 Axis contributes to E-cadherin Loss and Aggressiveness of Diffuse Gastric Cancer
| PRJNA721315 | ENA
Project description:This project identifies all the proteomic changes that take place in mouse embryonic stem cells after the knockout of the cell-cell adhesion protein E-cadherin. It identifies several putative pathways and sheds the light on the role of E-cadherin in controlling metabolsim of these pluripotent stem cells. The downregulation of E-cadherin resulted in the inhibiton of mitochondrial complex III and the upregulation of HIF-alpha-1 targets
2020-07-09 | PXD012679 | Pride
Project description:We conditionally substituted E-cadherin (E-cad; cadherin 1) with N-cadherin (N-cad; cadherin 2) during intestine development by generating mice in which an Ncad cDNA was knocked into the Ecad locus We used microarray to follow gene expression changes derived from lack of E-cadherin on intestinal epithelial cells
2017-05-01 | GSE81920 | GEO
Project description:Genome-wide analyses of the transcriptomes and transcription factor recruitment in estrogen receptor breast cancer cells in response to estradiol, IL1b, or TNFa treatments. Also, the role of inflammatory cytokines on affecting tamoxifen sensitivity is analyzed on a genome-wide scale.
2017-02-20 | GSE67295 | GEO
Project description:The aim of the experiment was to compare a newly defined population VE-Cadherin+GFP+ to control populations, VE-Cadherin- GFP+ and VE-Cadherin+GFP-.
2019-04-20 | GSE113403 | GEO
Project description:Increased N-cadherin expression is a pivotal hallmark and step in epithelial-to-mesenchymal transition (EMT), a trans differentiation process activated by colonic tumor cells to increase their spread and survival in a host organism. Although known to be associated with a considerable tumor aggressiveness and worse patient prognosis, exact mechanism(s) linking N-cadherin expression, EMT and aggressive biological phenotype of tumor cells are not entirely clear. In this study we used and compared two different in vitro cell models with varying N-cadherin expression, i.e. colon cancer cell lines HCT8 and SW480 with artificially upregulated expression of N-cadherin, and colon cancer cells with differing N-cadherin levels obtained from patients. Moreover, we have attempted to investigate the relationship between mesenchymal phenotype of cells (here represented by an increased expression of N-cadherin) and the degree of their chemoresistance. We report that although enforced N-cadherin expression changes select morphological and behavioral characteristics of exposed cells, it fails to successfully reprogram cells to the aggressive, chemoresistant phenotype both in vitro as well as in vivo upon implantation into athymic mice. Conversely, primocultures of patient-colonic cells with naturally high levels of N-cadherin expression show fully aggressive and chemoresistant phenotype pertinent to EMT (in vitro and in vivo), with a potential to develop new mutations and in the presence of dysregulated regulatory pathways as represented by investigated miRNA profiles. These results bring new facts concerning the functional axis of N-cadherin expression and related biological features of colon cancer cells and highlight the colon cancer primocultures as useful models for such studies.
2022-06-01 | GSE205027 | GEO
Project description:Expression of estrogen receptor (ESR1) determines whether a breast cancer patient receives endocrine therapy as part of their adjuvant care, but does not guarantee patient response. However, the molecular factors that define endocrine response in ESR1-positive breast cancer patients remain poorly understood. Here, we characterize the DNA methylome of endocrine sensitivity and demonstrate the potential impact of differential DNA methylation on endocrine response in breast cancer. We show that DNA hypermethylation occurs predominantly at estrogen-responsive enhancers and is associated with reduced ESR1 binding and decreased gene expression of key regulators of ESR1-activity; thus providing a novel mechanism by which endocrine response is abated in ESR1-positive breast cancers. Conversely, we delineate that ESR1-responsive enhancer hypomethylation is critical in transition from normal mammary epithelial cells to endocrine responsive ESR1-positive cancer. Cumulatively these novel insights highlight the potential of ESR1-responsive enhancer methylation to both predict ESR1-positive disease and stratify ESR1-positive breast cancer patients as responders to endocrine therapy. Methylation profiling with Illumina's HumanMethylation450K array was performed on ESR1-positive hormone sensitive MCF7 cells, and three different well characterised endocrine resistant MCF7-derived cell lines; tamoxifen-resistant (TAMR), fulvestrant-resistant (FASR) and estrogen deprivation resistant (MCF7X) cells. For each cell line two biological replicates were profiled bringing the number of samples to eight.
2015-07-01 | E-GEOD-69118 | biostudies-arrayexpress
Project description:Purpose. Aggressiveness is a crucial issue related to cutaneous melanoma malignancy and its high metastatic potential. Aim of this work is to identify new pathways or molecules controlling melanoma cell aggressiveness. Proliferation, migration and invasion capability under serum stimulation were analyzed in 12 human metastatic melanoma cell lines to identify the most aggressive ones as a model. The most proliferating/invading (defines as the most aggressive) A375 cell line was compared to the less aggressive one, Sk mel 28 by means of different approaches: 1) transcriptomic analysis by ILLUMINA platform; 2) proteomic study through LC-MS/MS analysis; 3) multiplexed assay to measure secretion of cytokines in conditioned media bioinformatic analysis was then carried out. Two groups of cells significantly differing in aggressiveness were identified and 2 cell lines, namely A375 and SK-Mel-28 were selected as model of the most and the less aggressive phenotype, respectively. A multi-omic analysis of several experimental datasets derived from transcriptomic, proteomic (mass spectrometric) and cytokinomic data was then carried out via Ingenuity Pathway Analysis (IPA) software. Analysis of upstream regulators and network analysis, indicated that the expression of tumor necrosis factor (TNF) were significantly differently expressed and functioning. The involvement of these pathways was confirmed by functional validation studies as zymography and proliferation studies and the most significantly upregulated pathway (TNF-alfa) was tested. Five melanoma cell lines with different MAGS were treated with an anti-TNFα monoclonal antibody and the most aggressive ones were highly significantly affected.
2019-01-08 | E-MTAB-4212 | biostudies-arrayexpress
Project description:Expression of estrogen receptor (ESR1) determines whether a breast cancer patient receives endocrine therapy as part of their adjuvant care, but does not guarantee patient response. However, the molecular factors that define endocrine response in ESR1-positive breast cancer patients remain poorly understood. Here, we characterize the DNA methylome of endocrine sensitivity and demonstrate the potential impact of differential DNA methylation on endocrine response in breast cancer. We show that DNA hypermethylation occurs predominantly at estrogen-responsive enhancers and is associated with reduced ESR1 binding and decreased gene expression of key regulators of ESR1-activity; thus providing a novel mechanism by which endocrine response is abated in ESR1-positive breast cancers. Conversely, we delineate that ESR1-responsive enhancer hypomethylation is critical in transition from normal mammary epithelial cells to endocrine responsive ESR1-positive cancer. Cumulatively these novel insights highlight the potential of ESR1-responsive enhancer methylation to both predict ESR1-positive disease and stratify ESR1-positive breast cancer patients as responders to endocrine therapy.
2015-07-01 | GSE69118 | GEO